Cetraxal Otic is one of the latest high quality branded pharmaceutical products  that has been discovered, manufactured and marketed by the world renowned Spanish pharmaceutical group known as Laboratorios Salvat. Salvat has been most successfully catering to the patients from over a dozen of the countries in the world with several of its prescription and over-the-counter pharmaceuticals products. Salvat is the independent, privately owned, Spanish pharmaceuticals group which is closely identified with technology innovations as well as strongly committed to R&D.

Cetraxal Otic is the solution with 0.2%, produced by using Ciprofloxacin as one of its key raw materials and is exclusively meant for the treatments of external Otitis. Laboratorios Salvat has received the notification in the form of an approval letter from the Foods and Drugs Administration, the United States regulatory authority toward the acceptance of the Cetraxal Otic Solution 0.2% dossier. However, the final approval still depends on the submission of the ultimate product packaging by the drug producers.

Cetraxal Otic is the suitable single dispensing container called SDC format by the US-FDA. The basis of the drug’s application would be assessed on the efficiency and safety of the treatment on the 630 patient clinical trials. The company has combined the benefits of the established, effective antibiotic with the simple yet appropriate form of administration. Company’s intention behind its product is for minimizing the needless ingredients for avoiding the unanticipated adverse reactions, specifically problematic in the pediatric population. The product is highly effective for the indication of external otitis providing more expediency without the risk of steroids, amino glycosides and preservatives.